Keine Story von Lupin Ltd mehr verpassen.
  • 22.02.2013 – 14:22

    Lupin Receives FDA Approval for New Drug Application for SUPRAX® Oral Suspension, 500 mg/5mL

    Mumbai, India And Baltimore (ots/PRNewswire) - Approval to add to growing SUPRAX(R) Franchise Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX(R) (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence ...